Profusa, Inc. (NASDAQ: PFSA), a Bay Area-based digital health company, is transitioning from pre-revenue development to commercialization, offering promising opportunities for investors. Management has indicated potential revenue generation in one segment by 2026, with projections of reaching $250 million in total revenue through diverse product offerings by 2030.
Over the past decade, Profusa has invested $100 million in research and development, supported by $30 million from DARPA. The company boasts an accomplished team holding 80 patents and stands in a strong market position with no credible competitors. The total addressable market for its products is estimated at $10.5 billion, targeting chronic disease management, particularly for diabetes and peripheral artery disease (PAD).
Profusa’s flagship products include tissue oxygen monitoring and continuous glucose monitoring solutions. A significant part of the strategy involves the Lumee system, which facilitates real-time data gathering on tissue oxygen levels, offering vital insights for medical professionals during interventions. The technology caters to a $4.9 billion market segment growing at 8% annually.
Recently, Profusa launched a research version of its Lumee system aimed at the contract research organization (CRO) market. This move is anticipated to generate immediate revenue streams as pharmaceutical companies increasingly seek predictive biological data to enhance drug development processes.
Looking ahead, Profusa’s advancements in biosensing technology are expected to make a substantial impact in both the glucose monitoring market and oxygen monitoring sector, projecting potential revenues of up to $150 million and $100 million respectively by 2030.
Why this story matters
Key takeaway
Opposing viewpoint
